- Previous Close
9.61 - Open
9.70 - Bid 8.41 x 100
- Ask 8.59 x 100
- Day's Range
8.28 - 9.84 - 52 Week Range
5.15 - 13.03 - Volume
1,025,193 - Avg. Volume
881,469 - Market Cap (intraday)
910.724M - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
-- - EPS (TTM)
-1.11 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.13
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
www.tangotx.comRecent News: TNGX
View More
Performance Overview: TNGX
Trailing total returns as of 9/17/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TNGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TNGX
View MoreValuation Measures
Market Cap
1.03B
Enterprise Value
745.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.69
Price/Book (mrq)
4.16
Enterprise Value/Revenue
17.53
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-274.04%
Return on Assets (ttm)
-21.76%
Return on Equity (ttm)
-50.58%
Revenue (ttm)
42.51M
Net Income Avi to Common (ttm)
-116.49M
Diluted EPS (ttm)
-1.11
Balance Sheet and Cash Flow
Total Cash (mrq)
322.11M
Total Debt/Equity (mrq)
15.28%
Levered Free Cash Flow (ttm)
-63.78M
Research Analysis: TNGX
View MoreCompany Insights: TNGX
TNGX does not have Company Insights
Research Reports: TNGX
View MoreDaily – Vickers Top Buyers & Sellers for 09/05/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 08/21/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 08/02/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 07/29/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.